(a)-(d): The bone marrow biopsy shows mild hypercellularity (a, H&E 200×) and mild to moderate fibrosis (b, Reticulin stain, 200×). CD79a (c, 200×) and CD3 (d, 200×) immunostains highlight lymphoid ...
What causes myelofibrosis? Myelofibrosis develops in the bone marrow, where stem cells produce the main three types of blood cell: white blood cells, red blood cells, and platelets. When the bone ...
Myelofibrosis belongs to a group of rare diseases called myeloproliferative neoplasms, which are types of blood cancer. These neoplasms can progress to acute myeloid leukemia (AML). In ...
Myelofibrosis causes an abnormal increase in the cells that produce collagen fibers called fibroblasts. The bone marrow becomes filled with these fibers, preventing the body from producing blood cells ...
Myelofibrosis causes an abnormal increase in the cells that produce collagen fibers called fibroblasts. The bone marrow becomes filled with these fibers, preventing the body from producing blood cells ...
Earlier treatment with Jakafi showed promise in both improving survival and symptom burden in certain patients with myelofibrosis, though physicians often delay Jakafi treatment. A higher percentage ...
Pelabresib plus Jakafi led to a reduction in spleen size and was tolerable in patients with myelofibrosis, according to data from MANIFEST-2. The addition of pelabresib to Jakafi (ruxolitinib) tended ...
The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group focused ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results